Acknowledgement

This activity is provided by Talem Health and RME Collaborative.

This activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc. 

Credit Available

• Physicians — maximum of 0.75 AMA PRA Category 1 Credit™
• Nurses — 0.75 Contact Hour (0.25 contact hour of pharmacotherapy credit)
• Pharmacists — 0.75 Contact Hour (0.075 CEU)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed specifically for primary care clinicians, nurses, eye care specialists (retinal specialists, ophthalmologists, and optometrists), and other members of the healthcare team who care for patients from rural and underserved communities.

Program Overview

When patients present with sudden or unexplained changes in vision, retinal vein occlusion (RVO) should be considered among the potential causes. This condition, which often occurs in individuals with systemic vascular risk factors such as hypertension, diabetes, and dyslipidemia, can lead to significant visual impairment if not promptly recognized and referred to a specialist. This activity, part of the four-part series entitled Eye on Access: A Longitudinal Approach to Closing the Gaps in Retinal Disease Care in Rural and Underserved Communities, will review how primary care clinicians can identify warning signs of RVO, manage associated comorbidities, and facilitate timely evaluation by an eye care specialist. Expert faculty will also discuss advances in anti-VEGF therapy and collaborative strategies to optimize patient outcomes through early detection, coordinated care, and ongoing monitoring. 

The content for this enduring activity was recorded on September 25, 2025.

Learning Objectives

Upon completion of this activity, participants should be better able to:  

• Identify common clinical presentations of RVO and how it differs from other causes of vision loss 
• Recognize risk factors and comorbid conditions associated with RVO, including systemic diseases 
• Apply appropriate referral protocols to ensure timely evaluation of patients with suspected RVO 
• Summarize treatment approaches for RVO and their relevance to improving visual outcomes 

Faculty

Rishi P. Singh, MD
Chair, Massachusetts Eye and Ear
Mass General Brigham
Boston, MA

Cody A. Chastain, MD, MEHP
Associate Professor of Medicine
Vanderbilt University Medical Center
Nashville, TN

Joint Accreditation Statement

In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

Credit Designation Statement

Physician Continuing Medical Education
Talem Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour. Designated for 0.25 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

Continuing Pharmacy Education
Talem Health designates this continuing education activity for 0.75 contact hour (0.075 CEU) of the Accreditation Council for Pharmacy Education. 
(Universal Activity Number – JA4008332-0000-25-076-H01-P) 
Type of Activity: Knowledge

Disclosure of Conflicts of Interest

Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

All relevant financial relationships have been mitigated. 

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty

Rishi P. Singh, MD, has disclosed the following relevant financial relationships: consultant/advisory board member for Alcon, Inc., Apellis Pharmaceuticals, Inc., Bausch + Lomb, EyePoint Pharmaceuticals, Inc., Genentech, Inc., Iveric Bio/Astellas Pharma, Inc., Regeneron Pharmaceuticals, Inc., Regenxbio, Inc., and ZEISS Group International; grant/research support from Janssen Pharmaceuticals, Inc.

Cody A. Chastain, MD, MEHP, has no relevant financial relationships to disclose.

Planners, Managers, and Reviewer 

The Talem Health planners, managers, and reviewer have nothing to disclose.

Instructions for Participation and Credit

This activity is offered at no cost to participants. To receive CME credit, participants must:

1. Read the CME/CE information, including learning objectives and disclosure statements.
2. Complete the pre-test.
3. View the online activity.
4. Complete the post-test and evaluation form.

A post-test score of 75% or higher is required to obtain credit. Your certificate will be made available for immediate download.

Course Viewing Requirements

Supported Browsers:
Desktop/laptop: Newest and last prior version of Google Chrome, Firefox, Safari, and Microsoft Edge
Mobile devices: Newest and last prior version of Safari and Google Chrome

Supported Phones & Tablets:
All devices

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

©RME Collaborative, a division of Talem Health, LLC. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.

Media

Internet activity

Fee Information

There is no fee for this educational activity.

Contact Information

For questions about this activity, please contact RME Collaborative (a division of Talem Health) at 800-913-9370 or cme@cmeruralhealth.com.